Cargando…

Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer

Discovery of the epidermal growth factor receptor gene mutation and the anaplastic lymphoma kinase chromosomal translocation in non-small cell lung cancer has prompted efforts around the world to identify many less common targetable oncogenic drivers. Such concerted efforts have been variably succes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daoud, Alia, Chu, Quincy S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626928/ https://www.ncbi.nlm.nih.gov/pubmed/29034207 http://dx.doi.org/10.3389/fonc.2017.00222

Ejemplares similares

Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion
por: Chu, Quincy S.
Publicado: (2020)

The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation
por: Cui, Jinfeng, et al.
Publicado: (2022)

Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer
por: Sweis, Randy F, et al.
Publicado: (2016)

Case Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma
por: Wang, Huan-You, et al.
Publicado: (2021)

Ultra-Deep Massive Parallel Sequencing of Plasma Cell-Free DNA Enables Large-Scale Profiling of Driver Mutations in Vietnamese Patients With Advanced Non-Small Cell Lung Cancer
por: Tran, Le Son, et al.
Publicado: (2020)

Advances in Lung Cancer Driver Genes Associated With Brain Metastasis
por: Kang, Yalin, et al.
Publicado: (2021)

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer
por: Lin, Chen, et al.
Publicado: (2020)

Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations
por: Liao, Jiatao, et al.
Publicado: (2021)

Selective Targeting of the L858R Mutation (EGFR) in Non-Small Cell Lung Cancer: A Mechanism for Advancing Targeted Chemotherapy
por: Arora, Rohan, et al.
Publicado: (2017)

Unique Profile of Driver Gene Mutations in Patients With Non-Small-Cell Lung Cancer in Qujing City, Yunnan Province, Southwest China
por: Zhou, Yongchun, et al.
Publicado: (2021)

Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma
por: Liu, Xia, et al.
Publicado: (2023)

Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer
por: Zhao, Yiming, et al.
Publicado: (2021)

Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
por: Pereira, Isabel, et al.
Publicado: (2020)

TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy
por: Liu, Surui, et al.
Publicado: (2022)

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation
por: Qu, Jingjing, et al.
Publicado: (2022)

Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors
por: Zhang, Runjiao, et al.
Publicado: (2021)

Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers
por: LIAM, Chong Kin, et al.
Publicado: (2023)

Chromosome Translocations as a Driver of Diversification in Mole Voles Ellobius (Rodentia, Mammalia)
por: Romanenko, Svetlana A., et al.
Publicado: (2019)

STRA6 Polymorphisms Are Associated With EGFR Mutations in Locally-Advanced and Metastatic Non-Small Cell Lung Cancer Patients
por: Muñiz-Hernández, Saé, et al.
Publicado: (2020)

Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Ma, Yuhui, et al.
Publicado: (2021)

CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
por: Kang, Liping, et al.
Publicado: (2023)

Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
por: Tartarone, Alfredo, et al.
Publicado: (2021)

The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures
por: Ferrara, Miriam Grazia, et al.
Publicado: (2021)

Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
por: Tibdewal, Anil, et al.
Publicado: (2021)

LAPS score for individualized treatment of advanced EGFR-mutated non-small cell lung cancer receiving EGFR-TKIs with or without bevacizumab
por: Wu, Yahua, et al.
Publicado: (2023)

Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
por: Jakobsen, Jan Nyrop, et al.
Publicado: (2018)

Whole exome sequencing identifies common mutational landscape of cervix and endometrium small cell neuroendocrine carcinoma
por: Wang, Wei, et al.
Publicado: (2023)

Strategies to target the cancer driver MYC in tumor cells
por: Weber, Leonie I., et al.
Publicado: (2023)

Clinical and pathological heterogeneity of four common fusion subtypes in Xp11.2 translocation renal cell carcinoma
por: Guo, Wei, et al.
Publicado: (2023)

Efficacy and safety of immune checkpoint inhibitors plus recombinant human endostatin therapy as second-line treatment in advanced non-small-cell lung cancer with negative driver gene: a pilot study
por: Yang, Bo, et al.
Publicado: (2023)

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
por: Barnes, Tristan A., et al.
Publicado: (2017)

Targeted Therapies and Biomarkers in Small Cell Lung Cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2020)

Targeting KRAS in Non-Small Cell Lung Cancer
por: Corral de la Fuente, Elena, et al.
Publicado: (2022)

Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Qian, Xiaohan, et al.
Publicado: (2021)

Recent and current advances in PET/CT imaging in the field of predicting epidermal growth factor receptor mutations in non-small cell lung cancer
por: Hu, Na, et al.
Publicado: (2022)

Integrated driver mutations profile of chinese gastrointestinal-natural killer/T-cell lymphoma
por: Li, Shanshan, et al.
Publicado: (2022)

Multidimensional Mutational Profiling of the Indian HNSCC Sub-Population Provides IRAK1, a Novel Driver Gene and Potential Druggable Target
por: Desai, Sagar Sanjiv, et al.
Publicado: (2021)

The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations—The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations
por: Tan, Jiarong, et al.
Publicado: (2021)

Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study
por: Gao, Xiaoxing, et al.
Publicado: (2022)

Histones and Their Modifications in Ovarian Cancer – Drivers of Disease and Therapeutic Targets
por: Marsh, Deborah J., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4gnm79oru4pohmqviqkp8j0m51